160 related articles for article (PubMed ID: 33149767)
1. PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer.
Loharamtaweethong K; Puripat N; Praditphol N; Thammasiri J; Tangitgamol S
Ther Adv Med Oncol; 2020; 12():1758835920963001. PubMed ID: 33149767
[TBL] [Abstract][Full Text] [Related]
2. Impact of antiretroviral drugs on PD-L1 expression and copy number gains with clinical outcomes in HIV-positive and -negative locally advanced cervical cancers.
Loharamtaweethong K; Vinyuvat S; Thammasiri J; Chitpakdee S; Supakatitham C; Puripat N
Oncol Lett; 2019 Dec; 18(6):5747-5758. PubMed ID: 31788048
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.
Loharamtaweethong K; Supakatitham C; Vinyuvat S; Puripat N; Tanvanich S; Sitthivilai U
Asian Pac J Allergy Immunol; 2021 Dec; 39(4):309-318. PubMed ID: 31586491
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
5. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T
JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis.
Noori M; Yousefi AM; Zali MR; Bashash D
Front Oncol; 2022; 12():1021859. PubMed ID: 36591463
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC.
Ulas EB; Hashemi SMS; Houda I; Kaynak A; Veltman JD; Fransen MF; Radonic T; Bahce I
JTO Clin Res Rep; 2023 Sep; 4(9):100532. PubMed ID: 37681219
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV.
Lovane L; Tulsidás S; Carrilho C; Karlsson C
Sci Rep; 2024 Jun; 14(1):12974. PubMed ID: 38839923
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.
Albrecht T; Brinkmann F; Albrecht M; Lonsdorf AS; Mehrabi A; Hoffmann K; Kulu Y; Charbel A; Vogel MN; Rupp C; Köhler B; Springfeld C; Schirmacher P; Roessler S; Goeppert B
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918309
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance.
Chen L; Lucas E; Zhang X; Liu Q; Zhuang Y; Lin W; Chen H; Zhou F
Histopathology; 2022 Jan; 80(2):338-347. PubMed ID: 34455625
[TBL] [Abstract][Full Text] [Related]
16. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.
Sato R; Komatsuda H; Inoue T; Wakisaka R; Kono M; Yamaki H; Ohara K; Kumai T; Kishibe K; Hayashi T; Takahara M
Head Neck; 2024 Apr; ():. PubMed ID: 38665131
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.
Zhang T; Liu Q; Zhu Y; Zhang S; Peng Q; Strickland AL; Zheng W; Zhou F
Cancer Manag Res; 2021; 13():9157-9165. PubMed ID: 34934360
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes.
Sun X; Liu L; Wan T; Huang Q; Chen J; Luo R; Liu J
Cancer Cell Int; 2022 Nov; 22(1):348. PubMed ID: 36376881
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
